ETCTN Trials by Disease/Treatment Area: Genitourinary Cancer

Genitourinary Cancer (various)

- A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIp) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

- A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option

- A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

Genitourinary cancer (various) - Urothelial cancer

- A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects

- A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)

- Phase 2 Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Urothelial cancer

- A Phase I Study of AZD8156 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Expansion: solid tumors; dose expansion includes breast, prostate, and solid tumor cohorts)

- A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

- A Phase I Study of AZD3755 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

Prostate cancer

- A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma (Escalation: solid tumors; urothelial cancer only)

Castration-resistant prostate cancer

Renal cell carcinoma

- An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

- A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

- A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects

- A Phase I Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors (Expansion phase Pt. 1 includes melanoma, renal cell, ovarian, and colorectal cancer)

Progressive renal cell carcinoma

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 15, 2020